LMO2 and breast cancer: However, further analysis of the samples grouped by the PAM50 subtype revealed that, in basal-type breast cancers, LMO2 expression tended to be higher in samples with lymph node metastasis than in those without, although this difference did not reach statistical significance (Δ x ̄=0.261, p=0.128, Figure 1B).